Evidence map›Paper›PMID 35403488›Full record

ArticlePublic health reports (Washington, D.C. : 1974)

Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action.

Shelley N Facente, Rachel Grinstein, Janessa Broussard, Jessica Shost, Soraya Azari, Jennifer Siruno, Jose A Jimenez, Anne F Luetkemeyer, Katie Burk

Open access · hybridAbstract read
In one paragraph

Article in Public health reports (Washington, D.C. : 1974). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shelley N FacenteSchool of Public Health, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-7266-352X
Rachel GrinsteinSan Francisco Department of Public Health, San Francisco, CA, USA.
Janessa BroussardSan Francisco AIDS Foundation, San Francisco, CA, USA.
Jessica ShostSan Francisco Health Plan, San Francisco, CA, USA.
Soraya AzariUniversity of California, San Francisco, San Francisco, CA, USA.
Jennifer SirunoUniversity of California, San Francisco, San Francisco, CA, USA.
Jose A JimenezFacente Consulting, Richmond, CA, USA.
Anne F LuetkemeyerUniversity of California, San Francisco, San Francisco, CA, USA.
Katie BurkFacente Consulting, Richmond, CA, USA.
San Francisco Department of Public Health · USSan Francisco General Hospital · USBerkeley Public Health Division · USSan Francisco AIDS Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until the COVID-19 pandemic, San Francisco's hepatitis C virus (HCV) elimination initiative, End Hep C SF, was expanding and refining HCV testing and treatment strategies citywide, making progress toward local HCV elimination goals. Although a shelter-in-place health order issued in March 2020 categorized HCV testing as an "essential service," most HCV testing and treatment immediately stopped until COVID-19-safe protocols could be implemented. During the 14 months of pandemic-related organizational closures, End Hep C SF transitioned to a 100% virtual model, maintaining regularly scheduled meetings. Community-based HCV antibody testing decreased 80% from February to April 2020, and HCV treatment initiation also decreased, although both services started to rebound in mid-to-late 2020, partially as a result of End Hep C SF collaborations. End Hep C SF service providers, clinicians, and advocates reported that the continuous communication and common agenda of End Hep C SF-2 principles of the collective impact initiative-served as a familiar touchpoint and helpful source of information during this isolating and uncertain time. Ultimately, End Hep C SF allowed us to continue HCV elimination strategies through 6 lessons learned: maintaining HCV treatment access through telehealth and mobile services; leveraging research studies that provided HCV testing and treatment; offering HCV screening and linkage to care in tandem with COVID-19-related initiatives; being flexible and inventive, such as administering HCV treatment to residents of shelter-in-place hotels; establishing a data dashboard to track HCV testing and treatment; and relying on partnerships to solve problems and avoid burnout.

Indexed as

COVID-19Hepatitis CHepacivirusHepatitis C AntibodiesHumansPandemicsHepatitis C AntibodiesCOVID-19eliminationHCVhepatitis Cpandemicresiliencescreeningtreatment

Identifiers

PMID35403488
PMCPMC9257501
OpenAlexW4223555067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.